A few interesting points I took note of:
The preparation of 700g of highly pure (>99% purity) reference grade MPL by PharmAust’s subsidiary Epichem. This MPL will be used for future preclinical work as required by PharmAust.
Continued discussions with clinicians willing to conduct human clinical trials examining the effects of MPL against cancer.
To receive Agreement from Vet Major which enables PharmAust to commercially develop an anti-viral MPL-based product against SARS CoV2 or COVID-19).
To complete optimization research on the MPL tablet to create a more tailored human product. The current tablet is sufficient for human work, but further optimization will permit greater flexibility in dosing and for targeting a wider range of human conditions in addition to cancer, such as viral infections (COVID-19) and neurodegenerative disorders.
To identify Clinical Centres prepared to evaluate the new MPL tablet in humans with COVID-19 and neurodegenerative diseases. PharmAust has already commenced discussions with several Centres regarding the same and has made good progress to date.
EPICHEM PTY LTD - 100% OWNED SUBSIDIARY OF PAA.
Epichem, a fully owned subsidiary of PharmAust, is a profitable and award winning medicinal and synthetic chemistry company with expertise and capability in the field of drug development, discovery and design. Epichem provides specialised products and technical expertise to a worldwide customer base in the pharmaceutical, mining, agriculture and animal health sectors.
Epichem also manufactures Pharmaceutical Reference Materials and Fine Chemicals and supports the PharmAust Drug Development Pipeline with Lead Drug Development and Validation, Drug Candidate Pipeline Manufacture and Analysis, Drug reformulation, GMP synthesis and stability support as well as Drug Inventory dispensing to clinical trial centres.
Epichem finished the financial year strongly, exceeding projected revenue forecast of $3.32 million to achieve $3.54 million. This is in light of the Unity Ltd contract coming to an end sooner than expected and the COVID-19 Pandemic.
Epichem has increased its Business Development capability with Distribution Partners, BD Consultants, Lead Generation partners and the engagement of a Social Media and PR partner for the US, Europe, Asia and Australian Markets and has added additional internal resource for Marketing and Communications.
Epichem has also expanded its suite of products and services beyond its current portfolio to include Material Science and IP technology to service the Energy, Resources and Agriculture sectors.
Epichem continues to pursue opportunities to create our own IP portfolio. This will also allow Epichem to maximise the R&D Tax incentive, partner with key stakeholders to accelerate commercialisation as well as act as an R&D project incubator for PAA.
Epichem was awarded the 2019 WA Exporter Award for International Health and was also awarded two Biotechnology 2020 Awards for Most Innovative Chemistry Service Provider - Australia & Best in Organic Chemistry Solutions 2020. This is testament to Epichem’s expertise, experience and acknowledgement of its export capability and outcomes achievement.
Best Luck to all
(20min delay)